Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Rafarma Pharmaceuticals, Inc. (RAFA)
Sandy, UT, US
Rafarma Pharmaceuticals, Inc. is a diversified pharmaceutical enterprise that manufactures and distributes a range of medicinal products, including generic antibiotics and specialized drugs, within the Russian market. Its product portfolio encompasses anti-cancer medications, cephalosporin-derived compounds, and non-beta-lactam antibiotics. These are available in various formats such as injectable solutions, ampoules, pediatric suspensions, oral tablets, and capsules. Additionally, Rafarma develops and supplies treatments for injuries, ocular inflammatory conditions, and immunological ailments. In a collaborative effort with PlantEXT Ltd., the company is involved in the research and production of pioneering medical cannabis suppositories, specifically designed for individuals afflicted with inflammatory bowel disease. Originally incorporated as Johnston Acquisition Corp., the firm adopted its current name, Rafarma Pharmaceuticals, Inc., in October 2012. While headquartered in Sandy, Utah, its primary manufacturing and distribution operations are situated in Russia. Since October 19, 2020, Rafarma Pharmaceuticals, Inc. has functioned as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +7.14% | -7.69% | +50.00% | +118.78% | -33.33% | -79.31% | -96.72% | +1,900.00% | -95.56% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+1.1% Q1'25: +26.4% (vs Q1'24)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+33.3% ★ Q1'25: -25.0% (vs Q1'24)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+4.4% Q1'25: -0.4% (vs Q1'24)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+5.3% Q1'25: +33.1% (vs Q1'24)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+3.8% Q1'25: +2.9% (vs Q1'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'25: +0.0% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.05× Q1'25: 0.00× (vs Q1'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alexander Ageev | Secretary, Treasurer and Director | — | male |
| Anucha Phetpheng | Executive Vice-President for Thai Operations | — | male |
| Sergey Brusnitsin | Chief Financial Officer and Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RAFA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
